文献速递造血干细胞移植与细胞治疗

巴瑞替尼治疗难治性慢性移植物抗宿主病的1/2期研究

Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study.
PubMed 文献 · Blood Adv · 2026-01-01

这项单中心1/2期研究纳入24例对至少2线治疗难治的重度慢性移植物抗宿主病成人患者,采用患者内剂量递增设计,评估巴瑞替尼每日2 mg与4 mg两个剂量水平。两个剂量水平均未观察到剂量限制性毒性,6个月总缓解率为76.2%(95%CI 52.8-91.8),中位无失败生存期为19个月(95%CI 11-26)。

要点

  • 两个剂量水平均未观察到剂量限制性毒性,巴瑞替尼耐受性良好。
  • 6个月总缓解率76.2%(95%CI 52.8-91.8),各受累器官均见缓解。
  • 中位无失败生存期19个月(95%CI 11-26),治疗期间无死亡或恶性肿瘤复发。

核心结论

  • 巴瑞替尼在重度难治性cGVHD队列中耐受性良好,并表现出高比例的持久缓解,值得在更早期线和更大规模研究中进一步评估。

研究设计与样本

  • 单中心1/2期研究,纳入24例对至少2线治疗难治的重度cGVHD成人患者。
  • 采用患者内剂量递增设计,巴瑞替尼每日2 mg与4 mg两个剂量水平。
  • 试验注册号NCT02759731。

主要发现

  • 两个剂量水平均未观察到剂量限制性毒性。
  • 6个月总缓解率为76.2%(95%CI 52.8-91.8),所有受累器官均观察到缓解,包括硬化性皮肤和肺部。
  • 中位无失败生存期为19个月(95%CI 11-26),治疗期间无死亡或恶性肿瘤复发。
  • 患者报告和功能结局出现具有临床意义的改善。
  • 免疫相关研究显示巴瑞替尼显著降低CD4+和CD8+ T细胞中细胞因子诱导的信号传导(STAT磷酸化)及促炎细胞因子分泌。

临床怎么用

  • 对于对至少2线治疗难治的重度cGVHD成人患者,可考虑巴瑞替尼每日2 mg或4 mg,需在密切监测下使用。
  • 治疗中应关注各受累器官(包括硬化性皮肤和肺部)的缓解评估及患者报告结局的改善。

局限性

  • 单中心研究,样本量24例,结果需更大规模研究验证。
  • 研究为1/2期设计,尚需在更早期线患者中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Refractory chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation remains a leading cause of late morbidity and mortality among transplant survivors. Therapeutic targeting of the Janus kinase (JAK)-STAT pathway has proved to be an effective approach for cGVHD; however, toxicities and short response durability have limited the use of available agents. The safety and efficacy of the JAK 1/2 inhibitor baricitinib were investigated in patients with severe cGVHD refractory to at least 2 lines of therapy. This single-center phase 1/2 study enrolled 24 adult patients who received 2 dose levels (DLs) of baricitinib, 2 and 4 mg daily, in an intrapatient dose escalation study design. No dose-limiting toxicities were observed at either DL. Overall response rate at 6 months was 76.2% (95% confidence interval [CI], 52.8-91.8), with responses observed across all involved organs, including sclerotic skin and pulmonary. Median failure-free survival was 19 months (95% CI, 11-26), with no deaths or malignancy relapse on treatment. Clinically meaningful improvements in patient-reported and functional outcomes were seen in this highly morbid cohort. Immune correlative studies showed that baricitinib induced significant reductions in cytokine-induced signaling (STAT phosphorylation) in both CD4+ and CD8+ T cells and in proinflammatory cytokine secretion. Baricitinib was well tolerated and exhibited a high rate of durable responses in a cohort of patients with severe cGVHD, warranting further evaluation in earlier-line and larger-scale studies. This trial was registered at www.clinicaltrials.gov as NCT02759731.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Holtzman NG, Im A, Curtis L, et al. Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study. Blood Adv. 2026. PMID: 42200447. doi:10.1182/bloodadvances.2025018898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。